CAPR
Capricor Therapeutics, Inc.NASDAQHealthcare$32.11-1.34%ClosedMarket Cap: $1.47B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.06
P/S
0.00
EV/EBITDA
-11.25
DCF Value
$5.71
FCF Yield
-5.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.5%
ROA
-29.5%
ROIC
-33.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-29.2M | $-30.2M | $-0.62 | — |
| FY 2025 | $0.00 | NaN% | $-108.1M | $-105.0M | $-2.26 | — |
| Q3 2025 | $0.00 | -Infinity% | $-26.3M | $-24.6M | $-0.54 | — |
| Q2 2025 | $0.00 | -Infinity% | $-27.7M | $-25.9M | $-0.57 | — |
| Q1 2025 | $0.00 | -Infinity% | $-25.0M | $-24.4M | $-0.53 | — |
| Q4 2024 | $11.1M | -30.8% | $-7.7M | $-7.1M | $-0.16 | — |
| FY 2024 | $22.3M | -124.4% | $-42.6M | $-40.5M | $-1.15 | — |
| Q3 2024 | $2.3M | -422.1% | $-13.0M | $-12.6M | $-0.38 | — |
| Q2 2024 | $4.0M | -214.9% | $-11.6M | $-11.0M | $-0.35 | — |
| Q1 2024 | $4.9M | -126.2% | $-10.3M | $-9.8M | $-0.31 | — |
| Q4 2023 | $12.1M | 17.8% | $-1.3M | $-762.1K | $-0.02 | — |
| FY 2023 | $25.2M | -44.8% | $-24.1M | $-22.3M | $-0.83 | — |